• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion.

作者信息

Zhang Chunye, Yang Ming

机构信息

Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, United States.

Department of Surgery, University of Missouri, Columbia, MO, United States.

出版信息

Front Med (Lausanne). 2021 Nov 18;8:789859. doi: 10.3389/fmed.2021.789859. eCollection 2021.

DOI:10.3389/fmed.2021.789859
PMID:34869507
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8637206/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ab/8637206/06116561f95c/fmed-08-789859-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ab/8637206/06116561f95c/fmed-08-789859-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ab/8637206/06116561f95c/fmed-08-789859-g0001.jpg

相似文献

1
Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion.针对非酒精性脂肪性肝病及非酒精性脂肪性肝病相关肝细胞癌治疗的T细胞亚群：一种观点。
Front Med (Lausanne). 2021 Nov 18;8:789859. doi: 10.3389/fmed.2021.789859. eCollection 2021.
2
The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma.非酒精性脂肪性肝病相关肝细胞癌的新兴因素及治疗选择
Cancers (Basel). 2021 Jul 26;13(15):3740. doi: 10.3390/cancers13153740.
3
Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target.鲨烯环氧化酶驱动非酒精性脂肪性肝病诱导的肝细胞癌，并成为一个药物靶点。
Sci Transl Med. 2018 Apr 18;10(437). doi: 10.1126/scitranslmed.aap9840.
4
Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.退伍军人事务人群中与非酒精性脂肪性肝病相关的肝细胞癌的时间趋势。
Clin Gastroenterol Hepatol. 2015 Mar;13(3):594-601.e1. doi: 10.1016/j.cgh.2014.08.013. Epub 2014 Aug 19.
5
Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications.非酒精性脂肪性肝病相关肝细胞癌的流行病学及其影响
JGH Open. 2018 Jul 17;2(5):235-241. doi: 10.1002/jgh3.12070. eCollection 2018 Oct.
6
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.非酒精性脂肪性肝病所致肝细胞癌的流行趋势。
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29.
7
Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different?肝细胞癌筛查与非酒精性脂肪性肝病：二者有何不同？
J Clin Exp Hepatol. 2020 Sep-Oct;10(5):518-524. doi: 10.1016/j.jceh.2020.04.004. Epub 2020 Apr 18.
8
NAFLD Related-HCC: The Relationship with Metabolic Disorders.非酒精性脂肪性肝病相关肝细胞癌：与代谢紊乱的关系。
Adv Exp Med Biol. 2018;1061:55-62. doi: 10.1007/978-981-10-8684-7_5.
9
Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝细胞癌的临床特征和预后。
Can J Gastroenterol Hepatol. 2020 Jun 3;2020:4873875. doi: 10.1155/2020/4873875. eCollection 2020.
10
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.血清酰基肉碱谱的改变与非酒精性脂肪性肝病（NAFLD）和 NAFLD 相关的肝细胞癌的状态有关。
Sci Rep. 2019 Jul 23;9(1):10663. doi: 10.1038/s41598-019-47216-2.

引用本文的文献

1
Genomic Exploration of Nonalcoholic Fatty Liver Disease: Insights From Gene Expression and Variation in Morbidly Obese Individuals.非酒精性脂肪性肝病的基因组探索：来自病态肥胖个体基因表达和变异的见解
J Obes. 2025 May 5;2025:9245699. doi: 10.1155/jobe/9245699. eCollection 2025.
2
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.代谢功能障碍相关脂肪性肝病驱动的肝细胞癌的药物治疗
Front Pharmacol. 2024 Jan 19;14:1336216. doi: 10.3389/fphar.2023.1336216. eCollection 2023.
3
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.

本文引用的文献

1
The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma.非酒精性脂肪性肝病相关肝细胞癌的新兴因素及治疗选择
Cancers (Basel). 2021 Jul 26;13(15):3740. doi: 10.3390/cancers13153740.
2
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.WSX1 通过下调肿瘤 PD-L1 表达在肝细胞癌中发挥肿瘤抑制作用。
Nat Commun. 2021 Jun 9;12(1):3500. doi: 10.1038/s41467-021-23864-9.
3
Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.吡非尼酮可改变 MAFLD/NASH 模型中的肝 miRNA 表达。
代谢相关脂肪性肝病（MAFLD）发病机制的新见解：肠-肝-心轴的相互作用
Nutrients. 2023 Sep 14;15(18):3970. doi: 10.3390/nu15183970.
4
Nutrition deprivation affects the cytotoxic effect of CD8 T cells in hepatocellular carcinoma.营养剥夺影响CD8 T细胞在肝细胞癌中的细胞毒性作用。
World J Gastrointest Oncol. 2022 Sep 15;14(9):1887-1891. doi: 10.4251/wjgo.v14.i9.1887.
5
Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy.调节性 T 细胞及其相关因素在肝细胞癌发生和治疗中的作用。
World J Gastroenterol. 2022 Jul 21;28(27):3346-3358. doi: 10.3748/wjg.v28.i27.3346.
6
Cancer Immunotherapy and Delivery System: An Update.癌症免疫疗法与递送系统：最新进展
Pharmaceutics. 2022 Aug 4;14(8):1630. doi: 10.3390/pharmaceutics14081630.
7
Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis.三种泛素结合酶2基因在肝细胞癌诊断和预后中的作用
World J Hepatol. 2022 May 27;14(5):956-971. doi: 10.4254/wjh.v14.i5.956.
8
Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options.肝细胞癌与肥胖症、2 型糖尿病、心血管疾病：致病因素、分子关联及治疗选择。
Front Endocrinol (Lausanne). 2021 Dec 23;12:808526. doi: 10.3389/fendo.2021.808526. eCollection 2021.
9
Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment.饮食与肠道微生物群相互作用衍生的代谢产物以及非酒精性脂肪性肝病发生发展和治疗中的肝内免疫反应
Biomedicines. 2021 Dec 13;9(12):1893. doi: 10.3390/biomedicines9121893.
Sci Rep. 2021 Jun 3;11(1):11709. doi: 10.1038/s41598-021-91187-2.
4
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.美国食品药品监督管理局批准摘要：纳武利尤单抗联合伊匹木单抗用于治疗既往接受过索拉非尼治疗的肝细胞癌患者。
Oncologist. 2021 Sep;26(9):797-806. doi: 10.1002/onco.13819. Epub 2021 Jun 10.
5
Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.肝细胞 miR-34a 是非酒精性脂肪性肝病发生发展的关键调节因子。
Mol Metab. 2021 Sep;51:101244. doi: 10.1016/j.molmet.2021.101244. Epub 2021 Apr 28.
6
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
7
A Role in the Genetic Predisposition to NAFLD-HCC?在非酒精性脂肪性肝病-肝癌的遗传易感性中起作用？
Cancers (Basel). 2021 Mar 19;13(6):1412. doi: 10.3390/cancers13061412.
8
Auto-aggressive CXCR6 CD8 T cells cause liver immune pathology in NASH.自反应性 CXCR6+CD8 T 细胞导致 NASH 肝脏免疫病理。
Nature. 2021 Apr;592(7854):444-449. doi: 10.1038/s41586-021-03233-8. Epub 2021 Mar 24.
9
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
10
NAFLD and MAFLD as emerging causes of HCC: A populational study.非酒精性脂肪性肝病和代谢功能障碍相关脂肪性肝病作为肝细胞癌的新发病因：一项人群研究。
JHEP Rep. 2021 Jan 19;3(2):100231. doi: 10.1016/j.jhepr.2021.100231. eCollection 2021 Apr.